| ID | 1100 |
| Name of the vaccine | Vaxchora |
| Microbe | Bacteria |
| Disease name | Cholera |
| Name of bacteria | Vibrio cholerae |
| Type of vaccine | Live attenuated |
| Nucleic acid content | DNA |
| Age | 2 to 64 years |
| Description of the vaccine | Vibrio cholerae serogroup O1 vaccine. |
| Name of the manufacturer | Emergent Travel Health Inc. |
| Name of the manufacturing country | United States |
| Year of manufacture | 2016 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram negative bacteria. |
| Efficacy | 90.3% effective 10 days after vaccination and 79.5% effective 90 days after vaccination. |
| Vaccine formulation | Lyophilized V. cholerae CVD 103-HgR. |
| Dosage | Single liquid dose, 10 days before the potential exposure. |
| Mechanism of action | Exposure to V. cholerae causes an elevation in baseline vibriocidal antibody titers which results in immunity. |
| Route of administration | Oral |
| Indications | Not been shown to protect against disease caused by V. cholerae serogroup O139 or other non-O1 serogroups. |
| Export | Distributed by - Emergent Travel Health Inc., USA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Tiredness, headache, abdominal pain, nausea, lack of appetite and diarrhoea. |
| Post vaccination | To avoid eating or drinking for 60 minutes before and after oral ingestion. |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/128415/download |
| Other name | NA |
| Additional Links | NA
|